Utilize este identificador para referenciar este registo: https://hdl.handle.net/1822/78412

Registo completo
Campo DCValorIdioma
dc.contributor.authorPereira, Ana Cláudia Santospor
dc.contributor.authorPina, André F.por
dc.contributor.authorSousa, Diana Andradepor
dc.contributor.authorFerreira, Débora Carina Gonçalves Abreupor
dc.contributor.authorCátia S. Pereirapor
dc.contributor.authorRodrigues, Joana Lúcia Lima Correiapor
dc.contributor.authorMelo, Luís Daniel Rodriguespor
dc.contributor.authorSales, M. G. F.por
dc.contributor.authorSousa, Sérgio F.por
dc.contributor.authorRodrigues, L. R.por
dc.date.accessioned2022-06-15T11:32:44Z-
dc.date.issued2022-03-17-
dc.identifier.citationPereira, A. C., Pina, A. F., Sousa, D., Ferreira, D., Santos-Pereira, C., Rodrigues, J. L., . . . Rodrigues, L. R. (2022). Identification of novel aptamers targeting cathepsin B-overexpressing prostate cancer cells. [10.1039/D2ME00022A]. Molecular Systems Design & Engineering, 7(6), 637-650. doi: 10.1039/d2me00022apor
dc.identifier.issn2058-9689por
dc.identifier.urihttps://hdl.handle.net/1822/78412-
dc.descriptionSupplementary files: https://www.rsc.org/suppdata/d2/me/d2me00022a/d2me00022a1.pdfpor
dc.description.abstractIncreased levels of cathepsin B (CatB), a cysteine protease, have been associated with different types of tumors, including prostate cancer. Hence, the identification of novel targeting ligands homing CatB may be a promising approach for the development of CatB-targeted therapies. In this work, a methodology called systematic evolution of ligands by EXponential enrichment (SELEX) was used to generate and isolate new aptamers targeting CatB. After 8 rounds of selection, the pool was sequenced, and the 10 most prevalent sequences, along with their corresponding reverse complementary sequences, were further analyzed. In order to assess the binding affinity of the aptamers towards the CatB, bioinformatics tools were used. After generating the 3D structures for each aptamer, the HADDOCK software was used for the docking studies between them and CatB. Molecular dynamics simulations and free binding energy calculations by molecular mechanics-generalized born surface area (MM-GBSA) allowed selection of a new aptamer with potential to target CatB. Cell binding assays against the PC-3 prostate cancer cell line confirmed the in silico predictions, further validating the newly discovered aptamer as a promising targeting ligand for CatB-overexpressing cancer cells.por
dc.description.sponsorshipThis study was supported by the Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UIDB/04469/2020 unit, the project UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences – UCIBIO, and the project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy – i4HB. Part of this work was produced with the support of INCD funded by FCT and FEDER under the project 01/SAICT/2016 no. 022153. Débora Ferreira (DF) and Ana Claudia Pereira (ACP) are the recipient of fellowships supported by a doctoral advanced training (call NORTE-69-2015-15) funded by the European Social Fund under the scope of Norte2020 – Programa Operacional Regional do Norte. André F. Pina acknowledges FCT for his Ph.D grant SFRH/BD/136594/2018. Diana A. Sousa acknowledges FCT for her grant PD/BD/139083/2018. Cátia Santos-Pereira acknowledges the Ph.D. fellowship (PD/BD/128032/2016) funded by FCT under the scope of the doctoral program in Applied and Environmental Microbiology (DP_AEM). Sérgio F. Sousa acknowledges FCT for funding through program 2020.01423.CEECIND.por
dc.language.isoengpor
dc.publisherRoyal Society of Chemistrypor
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04469%2F2020/PTpor
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04378%2F2020/PTpor
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04378%2F2020/PTpor
dc.relationinfo:eu-repo/grantAgreement/FCT/POR_NORTE/SFRH%2FBD%2F136594%2F2018/PTpor
dc.relationinfo:eu-repo/grantAgreement/FCT/POR_NORTE/PD%2FBD%2F139083%2F2018/PTpor
dc.relationinfo:eu-repo/grantAgreement/FCT/POR_NORTE/PD%2FBD%2F128032%2F2016/PTpor
dc.relationinfo:eu-repo/grantAgreement/FCT/CEEC IND 3ed/2020.01423.CEECIND%2FCP1596%2FCT0003/PTpor
dc.rightsrestrictedAccesspor
dc.titleIdentification of novel aptamers targeting cathepsin B-overexpressing prostate cancer cellspor
dc.typearticle-
dc.peerreviewedyespor
dc.relation.publisherversionhttps://pubs.rsc.org/en/content/articlelanding/2022/ME/D2ME00022Apor
dc.commentsCEB55414por
oaire.citationStartPage637por
oaire.citationEndPage650por
oaire.citationIssue6por
oaire.citationVolume7por
dc.date.updated2022-06-11T12:31:52Z-
dc.identifier.eissn2058-9689por
dc.identifier.doi10.1039/D2ME00022Apor
dc.date.embargo10000-01-01-
dc.description.publicationversioninfo:eu-repo/semantics/publishedVersion-
dc.subject.wosScience & Technologypor
sdum.journalMolecular Systems Design & Engineeringpor
Aparece nas coleções:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
document_55414_1.pdf
Acesso restrito!
4,32 MBAdobe PDFVer/Abrir

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID